Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
Richard E. Pratley, Katherine R. Tuttle, Peter Rossing, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1615-1628
Open Access | Times Cited: 22

Showing 22 citing articles:

Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1-RAs
Nikolaos Theodorakis, Maria Nikolaou
Biomedicines (2025) Vol. 13, Iss. 1, pp. 135-135
Open Access | Times Cited: 6
From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
Nikolaos Theodorakis, Maria Nikolaou
Biomolecules (2025) Vol. 15, Iss. 2, pp. 213-213
Open Access | Times Cited: 4
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant‐level pooled analysis of the CANVAS and CREDENCE trials
Safia Chatur, Muthiah Vaduganathan, Robert A. Fletcher, et al.
European Journal of Heart Failure (2025)
Open Access | Times Cited: 1
Efficacy of GLP-1 Receptor Agonists in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
Shoaib Waqas, Muhammad Umer Sohail, Muhammad Saad, et al.
Journal of Cardiac Failure (2025)
Open Access | Times Cited: 1
Nephrology: What You May Have Missed in 2024
Abdulla Alfadhel, Razan Alfarsi, Hussa Alkhajah, et al.
Annals of Internal Medicine (2025)
Closed Access | Times Cited: 1
Bewährtes und Neues in der Therapie der Herzinsuffizienz
Vedat Schwenger
Deleted Journal (2025)
Closed Access
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes
Patrizia Natale, Suetonia C. Green, David J. Tunnicliffe, et al.
Cochrane library (2025) Vol. 2025, Iss. 2
Closed Access
Glucagon-like peptide–1 receptor agonist for patients with heart failure with preserved ejection fraction and obesity
Linghua Fu, Yao Du, Pingping Yang, et al.
European Journal of Internal Medicine (2025)
Closed Access
Hypertension in chronic kidney disease and future heart failure
Michel Burnier
Current Opinion in Cardiology (2025)
Closed Access
Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies
S. Thompson, Ashwin Roy, Tarekegn Geberhiwot, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 624-624
Open Access
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
Richard Salvador, Carla Moutinho, Carla Silva, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 399-399
Open Access
Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease
Rashmi Thapa, Kyla Lara-Breitinger, Francisco López-Jiménez, et al.
JACC Advances (2025) Vol. 4, Iss. 4, pp. 101674-101674
Closed Access
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Takeshi Kitai, Shun Kohsaka, Takao Kato, et al.
Journal of Cardiac Failure (2025)
Closed Access
Semaglutide in heart failure and atherosclerotic cardiovascular disease: the current state-of-the-art
Nikolaos Theodorakis, Magdalini Kreouzi, Maria Nikolaou
Heart Failure Reviews (2025)
Closed Access
How to Enhance Cardiorenal Benefits in Patients With Chronic Heart Failure?
Toshihide Izumida, Koichiro Kinugawa
International Journal of Heart Failure (2025) Vol. 7
Open Access
Pathophysiology of vascular ageing and the effect of novel cardio‐renal protective medications in preventing progression of chronic kidney disease in people living with diabetes
Nikolaos Fountoulakis, Yoshihisa Miyamoto, Meda E. Pavkov, et al.
Diabetic Medicine (2024)
Open Access | Times Cited: 3
Estimated Reduction in Health Care Spending Associated With Weight Loss in Adults
Kenneth E. Thorpe, Peter J. Joski
JAMA Network Open (2024) Vol. 7, Iss. 12, pp. e2449200-e2449200
Closed Access | Times Cited: 3
Effects of GLP-1 Receptor Agonists on Heart Failure Outcomes
Veraprapas Kittipibul, Robert J. Mentz
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1629-1631
Closed Access | Times Cited: 2
Glomerular pressure and tubular oxygen supply: a critical dual target for renal protection
Takahiro Masuda, Daisuke Nagata
Hypertension Research (2024)
Closed Access | Times Cited: 1
Six substudies from the semaglutide trials: Identifying mechanisms of benefit and whom to treat
Neha J. Pagidipati
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1663-1665
Closed Access | Times Cited: 1
Pump, pipes, filter, sugar, weight, and more: the pluripotent prowess of semaglutide
Subodh Verma, Francesco Cosentino, Mikhail Kosiborod
European Heart Journal (2024)
Open Access | Times Cited: 1
European Society of Cardiology Congress 2024 Meeting: Heart Failure Highlights
Elena Donald, Alexander Hajduczok, Patricia Campbell
Journal of Cardiac Failure (2024)
Closed Access
What's new in heart failure? October 2024
Matthew M.Y. Lee, Pau Codina, Daniela Tomasoni, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 10, pp. 2049-2054
Open Access
Research Highlights
Paulomi Mehta, Natasha M. Rogers
Transplantation (2024)
Open Access
Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side
Aly M. Abdelrahman, Alaa S. Awad, Irtiza Hasan, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 24, pp. 7732-7732
Open Access
Page 1

Scroll to top